2 completed, 2 terminated, 1 unknown. 3 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Pharmatech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens Cancer | Unknown | Pharmatech | 183 | 2014-05-01 | 2016-04-25 | |
| Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma bendamustine, rituximab - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Pharmatech | 61 | 2008-11-01 | 2016-04-19 |
| Phase II Avastin Trial for Stage IIIB/IV NSCLC bevacizumab, docetaxel, carboplatin - Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 | Terminated | Pharmatech | 125 | 2008-10-01 | 2016-04-19 |
| Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan Cytoxan, Nipent, Rituxan - Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2005-06-01 | 2023-03-29 |
| Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer Trelstar, Lupron, Zoladex - Prostate Cancer | Phase 4 | Terminated | Pharmatech | 41 | 2002-09-01 | 2016-04-25 |
Lymphoma (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Prostatic Neoplasms (1)
Rituximab (2) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Goserelin (1) · Leuprolide (1) · Pentostatin (1) · Triptorelin Pamoate (1)
United States (4)
Chandra P Belani, MD (1) · Felipe Samaniego, MD (1) · Jeffrey L Vacirca, MD, FACP (1) · Matthew B Wiener, PharmD (1) · Michael Michael Manyak, MD (1)